From: Efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in nasopharyngeal carcinoma in vitro and in vivo
Group
TGI (%)
TGD500 (day)
TGD1000 (day)
Control
0
10.4
13.2
DDP
42
11.4
18.3
Evofosfamide 50 μmol/L
43
11.2
15.4
Evofosfamide 50 μmol/L + DDP
49
11.3
18.9
Evofosfamide 75 μmol/L
55
21.2
Evofosfamide 75 μmol/L + DDP
71
N/A